Comparative Pharmacology
Head-to-head clinical analysis: VIEKIRA PAK COPACKAGED versus VIEKIRA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIEKIRA PAK COPACKAGED versus VIEKIRA XR.
VIEKIRA PAK (COPACKAGED) vs VIEKIRA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VIEKIRA PAK combines three direct-acting antiviral agents (dasabuvir, ombitasvir, paritaprevir, and ritonavir) that inhibit hepatitis C virus (HCV) nonstructural proteins: ombitasvir inhibits NS5A, paritaprevir inhibits NS3/4A protease, dasabuvir inhibits NS5B RNA polymerase, and ritonavir boosts paritaprevir levels by inhibiting CYP3A4.
VIEKIRA XR contains dasabuvir, ombitasvir, paritaprevir, and ritonavir. Dasabuvir inhibits HCV NS5B RNA-dependent RNA polymerase, ombitasvir inhibits NS5A, paritaprevir inhibits NS3/4A protease, and ritonavir boosts paritaprevir levels via CYP3A4 inhibition.
Two tablets of ombitasvir 12.5 mg / paritaprevir 75 mg / ritonavir 50 mg once daily (morning) plus one tablet of dasabuvir 250 mg twice daily (morning and evening) with food.
VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir, ritonavir) extended-release tablets: 1 tablet (dasabuvir 250 mg, ombitasvir 12.5 mg, paritaprevir 75 mg, ritonavir 50 mg) orally once daily with a meal.
None Documented
None Documented
Dasabuvir: 5.5-7.1h; Paritaprevir: 5.5h; Ombitasvir: 21-25h; Ritonavir: 3-5h. Clinical context: Supports once-daily dosing for ombitasvir, twice-daily for others; half-lives may be prolonged in hepatic impairment.
Daunorubicin: 24-48 hours; daunorubicinol: 26-50 hours; clinically, the prolonged half-life contributes to cumulative cardiotoxicity risk.
Dasabuvir: 94.4% fecal (mostly unchanged), 1.9% renal; Paritaprevir: 88.0% fecal (mostly unchanged), 8.8% renal; Ombitasvir: 90.2% fecal, 1.9% renal; Ritonavir: 86% fecal, 11% renal.
Daunorubicin is eliminated via hepatic metabolism (daunorubicinol) and biliary excretion; renal excretion accounts for approximately 25% of total clearance, with 15-20% as unchanged drug and 5-10% as metabolites in urine over 72 hours; fecal excretion accounts for about 40% (mainly metabolites).
Category C
Category C
Hepatitis C Antiviral Combination
Hepatitis C Antiviral Combination